ArticleOpen forum infectious diseases2020
Short-term Peginterferon-Induced High Functional Cure Rate in Inactive Chronic Hepatitis B Virus Carriers With Low Surface Antigen Levels.
Article in Open forum infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05182463 (Real World Study of Peginterferon Alpha-2b Treatment for Inactive Chronic Hepatitis B Patients), which is not on this map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Real World Study of Peginterferon Alpha-2b Treatment for Inactive Chronic Hepatitis B Patients: E-Cure Study
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- The efficacy and safety of addition of pegylated interferon to long-term nucleos(t)ide analogue therapy on functional cure of chronic hepatitis B patient: a systematic review and meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Pegylated Interferon Treatment for the Effective Clearance of Hepatitis B Surface Antigen in Inactive HBsAg Carriers: A Meta-Analysis.Frontiers in immunology · 2021Pooled it
- Short-term pegylated interferon alpha in chronic HBV patients with ultra-low HBsAg: a retrospective study.Frontiers in cellular and infection microbiology · 2025Trial
- Association of PD-1BMC infectious diseases · 2026Article
- Dynamic changes in IFI44L and SAMHD1 mRNA levels in PBMCs are associated with treatment response in HBeAg-negative chronic hepatitis B during peg-IFN-α therapy.Frontiers in microbiology · 2026Article
- Defining success in functional cure for chronic hepatitis B: a nationwide survey of physician benchmarks to guide clinical practice and trial design.Frontiers in public health · 2026Article
- Peripheral Blood CD4Journal of clinical and translational hepatology · 2025Article
- [Analysis of the clinical characteristics of HBeAg-negative chronic HBV infection in indeterminate phase with a low viral load].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Article
- The impact of hepatitis B surface antigen seroconversion on the durability of functional cure induced by pegylated interferon alpha treatment.Virology journal · 2024Article
- Functional cure induced by tenofovir alafenamide plus peginterferon-alpha-2b in young children with chronic hepatitis B: a case series study.BMC infectious diseases · 2024Article
- [Chronic hepatitis B: from "treat only if" to "treat all"].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Article
- [Therapeutic strategies, practice, and prospect of a clinical cure for chronic hepatitis B in China].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Article
- Peg-IFNα combined with hepatitis B vaccination contributes to HBsAg seroconversion and improved immune function.Virology journal · 2024Article
- The Use of Tenofovir Disoproxil Fumarate in the Management of eAg-Negative Chronic Hepatitis B Infection.Journal of clinical medicine · 2024Article
- [Progress in the clinical cure of the population of inactive hepatitis B surface antigen carriers].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023Review
- Interferon stimulated immune profile changes in a humanized mouse model of HBV infection.Nature communications · 2023Article
- Short-Term Peg-IFN α-2b Re-Treatment Induced a High Functional Cure Rate in Patients with HBsAg Recurrence after Stopping Peg-IFN α-Based Regimens.Journal of clinical medicine · 2023Article
- Clinical cure induced by pegylated interferon α-2b in the advantaged population of chronic hepatitis B virus infection: a retrospective cohort study.Frontiers in cellular and infection microbiology · 2023Observational
- HBeAg-negative Patients with Chronic Hepatitis B Virus Infection and Normal Alanine Aminotransferase: Wait or Treat?Journal of clinical and translational hepatology · 2022Review
- Aiming for Functional Cure With Established and Novel Therapies for Chronic Hepatitis B.Hepatology communications · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNone of the current guidelines recommend antiviral therapy for inactive hepatitis B virus (HBV) carriers (IHCs).
methodsIn this real-world, multicenter, nonrandomized study, 32 participants meeting the inclusion criteria were enrolled 1:1 for treatment with peginterferon α-2b or monitoring without treatment based on participant preference. The expected treatment duration was 48 weeks. The primary end point was hepatitis B surface antigen (HBsAg) loss. The HBV vaccine could be injected after HBsAg loss.
resultsAll patients had HBsAg levels of <20 IU/mL. The mean baseline HBsAg levels were 6.6 IU/mL and 5.8 IU/mL in the treated and untreated groups, respectively. Fifteen (93.8%) participants achieved HBsAg loss, 5 obtained HBsAg seroconversion after undergoing a mean of 19.7 weeks of therapy in the treated group, and no one in the follow-up group achieved HBsAg loss during a mean follow-up time of 12.6 months (
conclusionsThis study provides justification for further studies of short-course peginterferon α-2b for the functional cure of IHCs with low HBsAg levels. Additionally, HBV vaccine injection is beneficial after interferon-induced HBsAg loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.